文献速递流行病学与生物统计真实世界研究与卫生经济

柳叶刀前列腺癌委员会:为病例激增规划应对策略

The Lancet Commission on prostate cancer: planning for the surge in cases.
PubMed 文献 · Lancet · 2024-04-04

前列腺癌是112个国家男性最常见的癌症,占癌症的15%。仅靠生活方式改变或公共卫生干预无法预防病例激增,各国政府需制定应对策略。委员会设立四个工作组分别考察流行病学与未来趋势、诊断路径、治疗及晚期疾病管理,并区分高收入国家与中低收入国家的问题,建议立即实施诊断路径改革并优化现有技术使用。

要点

  • 前列腺癌是112个国家男性最常见癌症,占全部癌症的15%。
  • 仅靠生活方式改变或公共卫生干预无法预防病例激增。

核心结论

  • 全球范围内晚期诊断普遍存在,尤其在中低收入国家为常态;早期诊断可改善预后和结局并降低社会和个人成本。
  • 中低收入国家的人口结构变化将驱动前列腺癌大幅增加,高收入国家病例也预计上升;若不采取紧急行动,全球前列腺癌死亡将快速上升。

研究设计与样本

  • 柳叶刀委员会报告,基于全球人口变化和预期寿命延长数据预测2040年前列腺癌病例数。
  • 设立四个工作组分别考察流行病学与未来预测趋势、诊断路径、治疗及晚期疾病管理。
  • 分析中区分高收入国家与低收入和中等收入国家,但承认该区分可能过于简化。

主要发现

  • 前列腺癌是112个国家男性中最常见的癌症,占癌症的15%。
  • 全球晚期诊断普遍,尤其在中低收入国家为常态;早期诊断可改善预后和结局并降低社会和个人成本。
  • 中低收入国家的人口结构变化将驱动前列腺癌大幅增加,高收入国家病例也预计上升。
  • 高收入国家年龄调整死亡率在下降,而中低收入国家在上升;非洲裔男性发病率约为欧洲裔男性的两倍,但多数前列腺癌研究不成比例地集中于欧洲裔男性。

关键数值与推荐

  • 推荐对诊断路径进行可立即实施的变化。
  • 对于诊断为晚期疾病的男性,根据可用资源水平调整优化使用现有技术可改善结局。
  • 应对病例增加需要紧急且激进的干预,尤其在中低收入国家,包括强调教育(卫生专业人员和公众)并联动外展项目以提高意识。

临床怎么用

  • 若实施上述干预,病例组合将从晚期疾病转向早期疾病,进而需要不同的治疗方式:早期诊断将促使从姑息治疗转向以手术和放疗为主的治愈性治疗。

局限性

  • 原文承认高收入国家与中低收入国家的区分可能过于简化(一些中低收入国家的富裕患者可获得高质量照护,而许多高收入国家尤其是美国的患者因保险覆盖不足而无法获得)。
  • 多数前列腺癌研究不成比例地集中于欧洲裔男性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Prostate cancer is the most common cancer in men in 112 countries, and accounts for 15% of cancers. In this Commission, we report projections of prostate cancer cases in 2040 on the basis of data for demographic changes worldwide and rising life expectancy. Our findings suggest that the number of new cases annually will rise from 1·4 million in 2020 to 2·9 million by 2040. This surge in cases cannot be prevented by lifestyle changes or public health interventions alone, and governments need to prepare strategies to deal with it. We have projected trends in the incidence of prostate cancer and related mortality (assuming no changes in treatment) in the next 10–15 years, and make recommendations on how to deal with these issues. For the Commission, we established four working groups, each of which examined a different aspect of prostate cancer: epidemiology and future projected trends in cases, the diagnostic pathway, treatment, and management of advanced disease, the main problem for most men diagnosed with prostate cancer worldwide. Throughout we have separated problems in high-income countries (HICs) from those in low-income and middle-income countries (LMICs), although we acknowledge that this distinction can be an oversimplification (some rich patients in LMICs can access high-quality care, whereas many patients in HICs, especially the USA, cannot because of inadequate insurance coverage). The burden of disease globally is already substantial, but options to improve care are already available at moderate cost. We found that late diagnosis is widespread worldwide, but especially in LMICs, where it is the norm. Early diagnosis improves prognosis and outcomes, and reduces societal and individual costs, and we recommend changes to the diagnostic pathway that can be immediately implemented. For men diagnosed with advanced disease, optimal use of available technologies, adjusted to the resource levels available, could produce improved outcomes. We also found that demographic changes (ie, changing age structures and increasing life expectancy) in LMICs will drive big increases in prostate cancer, and cases are also projected to rise in high-income countries. This projected rise in cases has driven the main thrust of our recommendations throughout. Dealing with this rise in cases will require urgent and radical interventions, particularly in LMICs, including an emphasis on education (both of health professionals and the general population) linked to outreach programmes to increase awareness. If implemented, these interventions would shift the case mix from advanced to earlier-stage disease, which in turn would necessitate different treatment approaches: earlier diagnosis would prompt a shift from palliative to curative therapies based around surgery and radiotherapy. Although age-adjusted mortality from prostate cancer is falling in HICs, it is rising in LMICs. And, despite large, well known differences in disease incidence and mortality by ethnicity (eg, incidence in men of African heritage is roughly double that in men of European heritage), most prostate cancer research has disproportionally focused on men of European heritage. Without urgent action, these trends will cause global deaths from prostate cancer to rise rapidly.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. James ND, Tannock I, N'Dow J, et al. The Lancet Commission on prostate cancer: planning for the surge in cases. Lancet. 2024. PMID: 38583453. doi:10.1016/S0140-6736(24)00651-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。